{
  "docId": "019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "docSlug": "jarvis-elliott-management-gsk-letter-july-2021",
  "documentTitle": "Elliott Management GSK Letter July 2021",
  "authorId": "elliott-management-gsk-letter-july-2021",
  "authorName": null,
  "documentKindSlug": "document",
  "documentKindLabel": "Document",
  "sourceTypeSlug": "independent_analyst",
  "sourceTypeLabel": "Independent analyst",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 3,
  "pageCount": 19,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide serves as a summary of the investment rationale, referencing detailed appendices for specific business units and valuation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019f6b8f-1354-774d-98d0-be219b0f6eb3/3",
  "deckHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "deckJsonHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3.json",
  "deckAnchorHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.68
      },
      "kind": "callout",
      "text": "CH and New GSK are two strong businesses that the market currently values far below their true potential. In our view, they warrant a combined valuation >45% higher than GSK's valuation today, especially as GSK progresses towards a full separation.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f7f04dc-0c27-46ec-aa2a-3be991a9c82e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.1,
        "y": 0.89
      },
      "kind": "other",
      "text": "Based on leading industry data providers. Leading management consulting firm analysis",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea74f8c1-abcb-42ba-a43c-8ded9e3a8b35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Elliott invested in GSK after extensive diligence, including consulting industry experts, former executives, investment banks, legal advisors, members of the scientific community, patient populations and other stakeholders, including dozens of GSK investors.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "467f5706-d0f7-4985-b10c-7ca50c443b0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.1,
        "y": 0.32
      },
      "kind": "paragraph",
      "text": "With its new autonomy and flexibility, Elliott believes that CH should be able to increase its growth rate (to at least the 5% growth of the consumer healthcare market), driven by improved execution and leadership.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76fc456f-e2b6-4530-88c0-4719ceee107d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.1,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "New GSK is also well positioned to exceed expectations. Having grown sales at a double-digit CAGR over the past 15 years, GSK's vaccines business is the global leader, with the widest product and technology portfolio.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e990f404-2cf0-49cb-babd-f2b78dbfa35b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.1,
        "y": 0.09
      },
      "kind": "title",
      "text": "Elliott's Process and Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ccefbb6-e0bd-4637-a634-7e1424ff4e77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.1,
        "y": 0.29
      },
      "kind": "title",
      "text": "GSK's Underappreciated Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e1babfb-b428-4c36-b3c5-3449918eab85",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "56202f1d-a7bd-4c1d-b462-d6ef76334654",
      "evidence": "Elliott invested in GSK after extensive diligence...",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 2,
      "beatId": "bb18563e-8738-45c7-a554-cf6ede7f9969",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Slides 2-6 focus on GSK's leadership role, the case for change, and the problem statement.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ce5898c8-a7b7-482e-ac1a-083005fd3875",
      "evidence": "The problem statement and closing ask imply a cost of inaction.",
      "position": 0,
      "objective": "Highlight the consequences of not changing",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}